Fintel reports that on November 4, 2025, BMO Capital maintained coverage of Terns Pharmaceuticals (NasdaqGS:TERN) with a Outperform recommendation.
Analyst Price Forecast Suggests 7.33% Downside
As of October 29, 2025, the average one-year price target for Terns Pharmaceuticals is $16.14/share. The forecasts range from a low of $7.51 to a high of $29.40. The average price target represents a decrease of 7.33% from its latest reported closing price of $17.42 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Terns Pharmaceuticals is 0MM, a decrease of 100.00%. The projected annual non-GAAP EPS is -1.95.
What is the Fund Sentiment?
There are 274 funds or institutions reporting positions in Terns Pharmaceuticals. This is an decrease of 26 owner(s) or 8.67% in the last quarter. Average portfolio weight of all funds dedicated to TERN is 0.11%, an increase of 60.77%. Total shares owned by institutions decreased in the last three months by 2.84% to 89,570K shares. 
The put/call ratio of TERN is 0.06, indicating a bullish outlook.
What are Other Shareholders Doing?
Soleus Capital Management holds 8,167K shares representing 9.33% ownership of the company. No change in the last quarter.
Orbimed Advisors holds 7,563K shares representing 8.64% ownership of the company. No change in the last quarter.
Deep Track Capital holds 7,495K shares representing 8.56% ownership of the company. In its prior filing, the firm reported owning 5,577K shares , representing an increase of 25.60%. The firm increased its portfolio allocation in TERN by 79.89% over the last quarter.
Vivo Capital holds 6,896K shares representing 7.88% ownership of the company. No change in the last quarter.
Citadel Advisors holds 3,899K shares representing 4.46% ownership of the company. In its prior filing, the firm reported owning 3,908K shares , representing a decrease of 0.23%. The firm increased its portfolio allocation in TERN by 23.45% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
